Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

James Vredenburgh

Showing results (31-40 of 40) with videos related to

Pageof 4
Sort By:
You have reached the last page of results.This site can display upto 40 results.
Cancer|August 10, 2005
Phase I trial of irinotecan plus temozolomide in adults with recurrent malignant gliomaDavid A Reardon, Jennifer A Quinn, Jeremy N Rich, et al.
International Journal of Radiation Oncology, Biology, Physics|September 15, 2009
Impact of high-dose chemotherapy on the ability to deliver subsequent local-regional radiotherapy for breast cancer: analysis of Cancer and Leukemia Group B Protocol 9082Lawrence B Marks, Constance Cirrincione, Thomas J Fitzgerald, et al.
Neuro-Oncology|December 18, 2019
Safety and efficacy of VB-111, an anticancer gene therapy, in patients with recurrent glioblastoma: results of a phase I/II studyAndrew J Brenner, Katherine B Peters, James Vredenburgh, et al.
Blood|October 24, 2002
Multi-institutional use of defibrotide in 88 patients after stem cell transplantation with severe veno-occlusive disease and multisystem organ failure: response without significant toxicity in a high-risk population and factors predictive of outcomePaul G Richardson, Carol Murakami, Zhezhen Jin, et al.
Neuro-Oncology|May 12, 2004
Phase 1 trial of irinotecan plus BCNU in patients with progressive or recurrent malignant gliomaJennifer A Quinn, David A Reardon, Allan H Friedman, et al.
Neuro-Oncology|May 12, 2004
Phase 2 trial of BCNU plus irinotecan in adults with malignant gliomaDavid A Reardon, Jennifer A Quinn, Jeremy N Rich, et al.
American Journal of Hematology|July 12, 2021
Romidepsin and lenalidomide-based regimens have efficacy in relapsed/refractory lymphoma: Combined analysis of two phase I studies with expansion cohortsNeha Mehta-Shah, Matthew A Lunning, Alison J Moskowitz, et al.
Journal of Neuro-Oncology|March 20, 2012
Apparent diffusion coefficient histogram analysis stratifies progression-free and overall survival in patients with recurrent GBM treated with bevacizumab: a multi-center studyWhitney B Pope, Xin Joe Qiao, Hyun J Kim, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 30, 2005
Phase I trial of temozolomide plus O6-benzylguanine for patients with recurrent or progressive malignant gliomaJennifer A Quinn, Annick Desjardins, Jon Weingart, et al.
American Journal of Hematology|August 29, 2019
Phase I/II trial of the CXCR4 inhibitor plerixafor in combination with bortezomib as a chemosensitization strategy in relapsed/refractory multiple myelomaIrene M Ghobrial, Chia-Jen Liu, Oksana Zavidij, et al.
Pageof 4

Showing results (31-40 of 40) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 40 results.
Cancer|August 10, 2005
Phase I trial of irinotecan plus temozolomide in adults with recurrent malignant gliomaDavid A Reardon, Jennifer A Quinn, Jeremy N Rich, et al.
International Journal of Radiation Oncology, Biology, Physics|September 15, 2009
Impact of high-dose chemotherapy on the ability to deliver subsequent local-regional radiotherapy for breast cancer: analysis of Cancer and Leukemia Group B Protocol 9082Lawrence B Marks, Constance Cirrincione, Thomas J Fitzgerald, et al.
Neuro-Oncology|December 18, 2019
Safety and efficacy of VB-111, an anticancer gene therapy, in patients with recurrent glioblastoma: results of a phase I/II studyAndrew J Brenner, Katherine B Peters, James Vredenburgh, et al.
Blood|October 24, 2002
Multi-institutional use of defibrotide in 88 patients after stem cell transplantation with severe veno-occlusive disease and multisystem organ failure: response without significant toxicity in a high-risk population and factors predictive of outcomePaul G Richardson, Carol Murakami, Zhezhen Jin, et al.
Neuro-Oncology|May 12, 2004
Phase 1 trial of irinotecan plus BCNU in patients with progressive or recurrent malignant gliomaJennifer A Quinn, David A Reardon, Allan H Friedman, et al.
Neuro-Oncology|May 12, 2004
Phase 2 trial of BCNU plus irinotecan in adults with malignant gliomaDavid A Reardon, Jennifer A Quinn, Jeremy N Rich, et al.
American Journal of Hematology|July 12, 2021
Romidepsin and lenalidomide-based regimens have efficacy in relapsed/refractory lymphoma: Combined analysis of two phase I studies with expansion cohortsNeha Mehta-Shah, Matthew A Lunning, Alison J Moskowitz, et al.
Journal of Neuro-Oncology|March 20, 2012
Apparent diffusion coefficient histogram analysis stratifies progression-free and overall survival in patients with recurrent GBM treated with bevacizumab: a multi-center studyWhitney B Pope, Xin Joe Qiao, Hyun J Kim, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 30, 2005
Phase I trial of temozolomide plus O6-benzylguanine for patients with recurrent or progressive malignant gliomaJennifer A Quinn, Annick Desjardins, Jon Weingart, et al.
American Journal of Hematology|August 29, 2019
Phase I/II trial of the CXCR4 inhibitor plerixafor in combination with bortezomib as a chemosensitization strategy in relapsed/refractory multiple myelomaIrene M Ghobrial, Chia-Jen Liu, Oksana Zavidij, et al.
Pageof 4